MTNB logo

Matinas BioPharma Holdings, Inc.

MTNB
Healthcare|Biotechnology|US
$1.19
+0.03 (+2.59%)
DCF Value
$6.44
Cash / Share
$1.78

Analyst Consensus

Buy8 analysts
Strong Buy
0
Buy
7
Hold
1
Sell
0
Strong Sell
0

Rating Trend

Jun 24
3 buy · 0 hold · 0 sell
Jul 24
3 buy · 0 hold · 0 sell
Aug 24
3 buy · 0 hold · 0 sell
Sep 24
4 buy · 0 hold · 0 sell
Oct 24
3 buy · 1 hold · 0 sell
Nov 24
3 buy · 2 hold · 0 sell
Dec 24
1 buy · 2 hold · 0 sell
Jan 25
0 buy · 2 hold · 0 sell
Feb 25
0 buy · 2 hold · 0 sell
May 25
0 buy · 2 hold · 0 sell
Jun 25
0 buy · 1 hold · 0 sell
Jul 25
0 buy · 1 hold · 0 sell

Recent Rating Actions

FirmActionRatingDate
Maxim GroupdowngradeBuy →HoldOct 31, 2024
HC Wainwright & Co.maintainBuyJan 31, 2023
Aegis CapitalmaintainBuyAug 13, 2020
Piper SandlermaintainOverweightJan 27, 2020
SunTrust Robinson HumphreymaintainBuyJan 24, 2020
H.C. WainwrightmaintainBuyJun 26, 2019
BTIG ResearchmaintainBuyMay 17, 2019
Roth CapitalmaintainBuyFeb 11, 2019
Maxim GroupmaintainBuyNov 13, 2018
Maxim GroupmaintainBuyAug 13, 2018
Maxim GroupmaintainBuyJul 10, 2018
Aegis CapitalmaintainBuyNov 1, 2016

Earnings History

Next report: Nov 12, 2026 · EPS est. $-19.76
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Aug 13, 2026$-3.15$-1.32—$25.0K
May 8, 2026$-0.30$-19.76—$25.0K
Mar 31, 2026$-0.26$-0.78—$25.0K
Nov 10, 2025$-0.40$-1.05—$25.0K
Aug 14, 2025$-1.03$-1.25——
May 15, 2025$-0.33$-1.50—$300.0K
Apr 4, 2025$-1.00$-1.50—$300.0K
Nov 13, 2024$-0.85$-15.75—$300.0K

News

GH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility Output

Agreement establishes GH Power's first commercial hydrogen offtake and validates hydrogen production from the Company's proprietary aluminum-water reactor platform Agreement establishes GH Power's first commercial hydrogen offtake and validates hydrogen production from the Company's proprietary aluminum-water reactor platform

Sep 14, 2026globenewswire.com
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

BEDMINSTER, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on August 31, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders' equity of at least $2.…

Sep 4, 2026globenewswire.com